期刊
BONE MARROW TRANSPLANTATION
卷 56, 期 4, 页码 779-785出版社
SPRINGERNATURE
DOI: 10.1038/s41409-020-01169-7
关键词
-
资金
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81621001]
- Key Program of National Natural Science Foundation of China [81530046]
- National Key Research and Development Program of China [2017YFA0104500]
- Peking University Clinical Scientist Program [BMU2019LCKXJ003]
HSCT is a curative option for SAA, with haploidentical donors providing expanded choices. Recent advancements in haplo-HSCT have overcome previous challenges and achieved inspiring survival outcomes in SAA. Different regimens such as G-CSF and ATG, PT-Cy, and TCD have been successful in promoting haplo-HSCT as a priority option for SAA patients without matched donors in China.
Haematopoietic stem cell transplantation (HSCT) is a curative option for severe aplastic anemia (SAA). Finding a suitable matched donor in a timely manner is a challenge. The availability of haploidentical donors and their successful use in transplantation have expanded valid choices for SAA. In recent decades, haploidentical HSCT (haplo-HSCT) for the treatment of SAA has been continuously attempted, and great strides have been made. Nowadays, haplo-HSCT using different regimens has overcome the difficulty of graft failure and severe graft-versus-host disease (GvHD), and achieved inspiring survival outcomes in SAA. The regimens consist mainly of granulocyte colony-stimulating factor (G-CSF) plus antithymocyte globulin (ATG), posttransplantation cyclophosphamide (PT-Cy), and ex vivo graft T-cell depletion (TCD). In particular, the G-CSF and ATG-based regimen includes the largest sample size and the successful wide use of the G-CSF and ATG-based regimen has promoted haplo-HSCT a higher priority in SAA patients without matched related or unrelated donors in China. Recent studies have also indicated that haplo-HSCT using PT-Cy or TCD regimen is a practicable alternative, but the sample size is relatively small. Here, we offer an overview of clinical results obtained through the use of haploidentical transplantation in SAA, mainly focusing on current advances and future challenges.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据